• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.

作者信息

Novi Giovanni, Ghezzi Angelo, Pizzorno Matteo, Lapucci Caterina, Bandini Fabio, Annovazzi Pietro, Mancardi Giovanni L, Uccelli Antonio

机构信息

Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) (N.G., C.L., G.L.M., A.U.), University of Genoa, Italy; Multiple Sclerosis Study Center (A.G., P.A.), Hospital of Gallarate, Italy; San Paolo Hospital (M.P., F.B.), Savona, Italy; and IRCCS AUO San Martino-IST (G.L.M., A.U.), Genoa, Italy.

出版信息

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e377. doi: 10.1212/NXI.0000000000000377. eCollection 2017 Sep.

DOI:10.1212/NXI.0000000000000377
PMID:28804745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5532747/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c3/5532747/4e21361a13cc/NEURIMMINFL2015007120FF1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c3/5532747/4e21361a13cc/NEURIMMINFL2015007120FF1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00c3/5532747/4e21361a13cc/NEURIMMINFL2015007120FF1.jpg

相似文献

1
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.停用芬戈莫德后，孕期多发性硬化症出现显著反弹。
Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e377. doi: 10.1212/NXI.0000000000000377. eCollection 2017 Sep.
2
Erratum: Dramatic rebounds of MS during pregnancy following fingolimod withdrawal.勘误：停用芬戈莫德后孕期多发性硬化症的剧烈反弹。
Neurol Neuroimmunol Neuroinflamm. 2018 Apr 12;5(3):e462. doi: 10.1212/NXI.0000000000000462. eCollection 2018 May.
3
Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.停用芬戈莫德后多发性硬化症患者的严重疾病加重
Neurol Neurochir Pol. 2017 Mar-Apr;51(2):156-162. doi: 10.1016/j.pjnns.2017.01.006. Epub 2017 Feb 2.
4
Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound.在一个 fingolimod 后 MS 反弹模型中，鞘氨醇 1 磷酸受体 1（S1P1）信号的失调和调节性淋巴细胞依赖性免疫抑制。
Brain Behav Immun. 2015 Nov;50:78-86. doi: 10.1016/j.bbi.2015.06.019. Epub 2015 Jun 27.
5
Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.对多发性硬化症患者进行脉冲式皮质类固醇治疗，可在停用那他珠单抗并转而使用芬戈莫德之前稳定疾病活动。
Int J Neurosci. 2016 Dec;126(12):1097-102. doi: 10.3109/00207454.2015.1127919. Epub 2016 Jan 4.
6
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.芬戈莫德可预防多发性硬化症患者血清诱导的血脑屏障破坏。
PLoS One. 2015 Mar 16;10(3):e0121488. doi: 10.1371/journal.pone.0121488. eCollection 2015.
7
Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.芬戈莫德（FTY720）对多发性硬化症患者脉络膜厚度的影响。
Mult Scler Relat Disord. 2017 May;14:4-7. doi: 10.1016/j.msard.2017.03.005. Epub 2017 Mar 16.
8
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.两例原发性进行性多发性硬化症患者停用芬戈莫德后复发的病例。
J Neurol. 2016 Jul;263(7):1361-3. doi: 10.1007/s00415-016-8144-x. Epub 2016 May 9.
9
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.在活动期多发性硬化症中，改用芬戈莫德或干扰素β/醋酸格拉替雷的比较。
JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147.
10
Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).芬戈莫德治疗复发缓解型多发性硬化症（MS）的心血管状况最新进展。
Mult Scler Relat Disord. 2016 Jul;8:19-26. doi: 10.1016/j.msard.2016.04.002. Epub 2016 Apr 21.

引用本文的文献

1
Patient-centered pregnancy planning in multiple sclerosis: evidence for a new era.以患者为中心的多发性硬化症妊娠规划：新时代的证据。
Arq Neuropsiquiatr. 2024 Oct;82(10):1-11. doi: 10.1055/s-0044-1791202. Epub 2024 Oct 2.
2
Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis.多发性硬化症中疾病修饰疗法的个性化应用
Pharmaceutics. 2024 Jan 17;16(1):120. doi: 10.3390/pharmaceutics16010120.
3
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.优化多发性硬化症女性的“受孕时间”：OPTIMUS德尔菲调查

本文引用的文献

1
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis: Are There Lessons to Be Learned?多发性硬化症患者停止另一种疾病修正治疗后的反弹复发：有什么经验教训？
JAMA Neurol. 2016 Jul 1;73(7):775-6. doi: 10.1001/jamaneurol.2016.0934.
2
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.多发性硬化症患者停用芬戈莫德后出现反弹综合征。
JAMA Neurol. 2016 Jul 1;73(7):790-4. doi: 10.1001/jamaneurol.2016.0826.
3
Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound.
Front Neurol. 2023 Oct 6;14:1255496. doi: 10.3389/fneur.2023.1255496. eCollection 2023.
4
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.多发性硬化症患者停止使用芬戈莫德后疾病活动和残疾的情况。
Neurol Neuroimmunol Neuroinflamm. 2023 May 22;10(4). doi: 10.1212/NXI.0000000000200110. Print 2023 Jul.
5
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.在一大群多发性硬化症患者的真实世界队列中，对停用芬戈莫德后疾病活动复发的频率、严重程度及独立危险因素进行评估。
Ther Adv Neurol Disord. 2023 Feb 6;16:17562864221150312. doi: 10.1177/17562864221150312. eCollection 2023.
6
The protective role of breastfeeding in multiple sclerosis: Latest evidence and practical considerations.母乳喂养在多发性硬化症中的保护作用：最新证据与实际考量
Front Neurol. 2023 Jan 24;13:1090133. doi: 10.3389/fneur.2022.1090133. eCollection 2022.
7
Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.孕期多发性硬化症管理挑战的最新观点
Degener Neurol Neuromuscul Dis. 2022 Jan 5;12:1-21. doi: 10.2147/DNND.S203406. eCollection 2022.
8
Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.鞘氨醇-1-磷酸（S1P）受体调节剂在多发性硬化症治疗中的滥用和依赖潜力：文献和公共数据回顾。
Psychopharmacology (Berl). 2022 Jan;239(1):1-13. doi: 10.1007/s00213-021-06011-6. Epub 2021 Nov 13.
9
Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy.为计划怀孕的临床稳定型复发缓解型多发性硬化症患者更换治疗方案。
Mult Scler J Exp Transl Clin. 2021 Mar 19;7(1):20552173211001571. doi: 10.1177/20552173211001571. eCollection 2021 Jan-Mar.
10
Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS.多发性硬化症患者妊娠及产后的临床和放射学疾病活动情况。
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 19;8(2). doi: 10.1212/NXI.0000000000000959. Print 2021 Mar.
在一个 fingolimod 后 MS 反弹模型中，鞘氨醇 1 磷酸受体 1（S1P1）信号的失调和调节性淋巴细胞依赖性免疫抑制。
Brain Behav Immun. 2015 Nov;50:78-86. doi: 10.1016/j.bbi.2015.06.019. Epub 2015 Jun 27.
4
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.在高度活跃的多发性硬化症患者中，停用那他珠单抗治疗后临床复发的复发或反弹。
J Neurol. 2014 Jun;261(6):1170-7. doi: 10.1007/s00415-014-7325-8. Epub 2014 Apr 12.
5
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.多发性硬化症 fingolimod 临床开发项目中的妊娠结局。
Neurology. 2014 Feb 25;82(8):674-80. doi: 10.1212/WNL.0000000000000137. Epub 2014 Jan 24.
6
Rebound of disease activity during pregnancy after withdrawal of fingolimod.停用芬戈莫德后孕期疾病活动的反弹
Eur J Neurol. 2013 Aug;20(8):e109-10. doi: 10.1111/ene.12195.
7
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.那他珠单抗治疗停止后多发性硬化症患者的免疫重建炎症综合征
Arch Neurol. 2011 Feb;68(2):186-91. doi: 10.1001/archneurol.2010.257. Epub 2010 Oct 11.